persistent gingival bleeding after scaling a diagnostic clue to von willebrand disease

Original title: “Persistent Gingival Bleeding After Scaling: A Diagnostic Clue to von Willebrand Disease.”

The Food and Drug Administration (FDA) is classifying the von Willebrand factor assay into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the von Willebrand factor assay. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will a

Original title: “Medical Devices; Hematology and Pathology Devices; Classification of the Von Willebrand Factor Assay”

type 3 von willebrand disease two clinical cases of a rare disorder

Original title: “Type 3 Von Willebrand disease: two clinical cases of a rare disorder.”

mucosal bleeding in a newborn with low factor viii activity an unusual combination of type 2a and type 2n von willebrand disease

Original title: “Mucosal Bleeding in a Newborn With Low Factor VIII Activity: An Unusual Combination of Type 2A and Type 2N von Willebrand Disease.”

Hemab Therapeutics, a Phase 3-ready biotech developing blood coagulation disorder treatments, filed on Friday with the SEC to raise up to $100 million in an initial public offering.Hemab is a clinical-stage biotechnology company developing antibody-based therapies for inherited bleeding and ... Hemab Therapeutics, a Phase 3-ready biotech developing blood coagulation disorder treatments, filed on Friday with the SEC to raise up to $100 million in an initial public offering.Hemab is a clinical-stage biotechnology company developing antibody-based therapies for inherited bleeding and coagulat... Hemab is a clinical-stage biotechnology company developing antibody-based therapies for inherited bleeding and coagulation disorders. Its lead candidate, sutacimig (HMB-001), finished Phase 2 and is ready for Phase 3 for Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency, while HMB-002 is in Phase 1/2 for Von Willebrand Disease. The company’s programs are focused on prophylactic subcutaneous treatments for rare disorders with limited existing options, and it is also advancing additional preclinical candidates in coagulation-related diseases.

Original title: “COAG IPO News - Coagulation disorder biotech Hemab Therapeutics files for a $100 million IPO”

real word evidence on healthcare resource use and associated costs in on demand users of replacement therapies in von willebrand disease in france the forvward study

Original title: “Real-word evidence on healthcare resource use and associated costs in on-demand users of replacement therapies in von Willebrand disease in France: the FORvWARD study.”